Acne 

Actinic Keratosis 

Aesthetics

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Dry Cracked Skin

Hidradenitis Suppurativa

Impetigo

Inflamed Skin

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Surgery

Vitiligo

Wound Care

News

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

DermView

Editorial Board News

Expert Interviews

Expert Perspectives

Fellows Face Off

Frontline Forum

Inside the Clinic

Medical World News

Partner Perspectives

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Image IQ

Interactive Tools

Job Board

Polls

Editorial Advisory Board

Partnerships

Subscribe

Print Subscription

eNewsletter

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

With greater understanding of this rare pathology and its signs and symptoms, review authors believe this understanding could prompt early and necessary intervention.

Greater Understanding Necessary in Treatment of Periorbital Facial Necrotizing Fasciitis, Review Argues

Each of 3 patients treated with cemiplimab achieved a near complete response.

First Real-World Report of Near Complete Response With Cemiplimab in Penile Squamous Cell Carcinoma, Study Confirms

A recent study linked alopecia areata and the presence of cochlear dysfunction in some patients.

Alopecia Areata Linked to Hearing Loss, Study Finds

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date

Heather Goff, MD, MPH

Articles